Review catalogs 136 human studies on sulforaphane and broccoli bioactives

By AI, Created 1:35 PM UTC, May 21, 2026, /AGP/ – A new peer-reviewed review in Medicines compiles 136 human clinical studies on sulforaphane, broccoli sprouts, and related interventions, pointing to broad research interest in metabolic, cognitive, inflammatory, and oncology applications. The paper also says most commercial broccoli seed and sprout studies in the reviewed subset used the TrueBroc ingredient family.

Why it matters: - The review pulls together three decades of human clinical evidence on sulforaphane and broccoli bioactives into one reference point for researchers, formulators, and clinicians. - The paper says the research base now spans health areas including metabolic health, cognition, inflammation, cardiovascular function, aging, detoxification, autism spectrum disorder, schizophrenia, oncology, and bioavailability. - The compendium may help clarify where sulforaphane research has strongest clinical depth and where formulation quality and dose still matter.

What happened: - A peer-reviewed paper titled “Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan” was published in Medicines on May 6, 2026. - The authors are Dr. Jed W. Fahey and Dr. Hua Liu of Johns Hopkins School of Medicine. - A supplemental compendium alongside the paper catalogs 136 human clinical studies using glucoraphanin, sulforaphane, broccoli sprouts, broccoli seed extracts, or related interventions. - The table covers studies dating back to 1998 and was updated through March 15, 2026.

The details: - The review says sulforaphane is derived from broccoli, broccoli seeds and sprouts, and other cruciferous vegetables. - The paper highlights possible synergy between sulforaphane and phytochemicals including EGCG, curcumin, selenium and quercetin. - The review also points to possible interactions with chemotherapy agents, targeted therapies and immunotherapies. - Across multiple models, the paper describes effects on Nrf2-mediated cytoprotective pathways, glutathione-related pathways, apoptosis, inflammation, oxidative stress response, epigenetic regulation and cancer stem cell signaling. - The publication stresses that intervention specifics matter because quality, dosage and sulforaphane bioavailability can affect outcomes, especially given sulforaphane’s instability. - Many of the cited studies used the TrueBroc family of ingredients. - An internal analysis of commercially available preparations found that about 79% of broccoli seed and sprout interventions used the TrueBroc family of ingredients. - The review is dedicated to the memory of Professor Thomas W. Kensler, who died in 2025.

Between the lines: - The paper is not just cataloging studies; it is framing sulforaphane as a multi-pathway compound with possible relevance beyond nutrition alone. - The emphasis on commercial versus lab-made preparations suggests the authors see formulation consistency as central to translating research into products and practice. - The heavy use of one ingredient family in the commercial subset may give TrueBroc added visibility in the market for broccoli-derived supplements. - The synergy discussion is promising, but it is still an interpretation of the evidence rather than proof of clinical superiority across all use cases.

What’s next: - The review is likely to be used as a reference for future clinical design, ingredient selection and bioavailability research. - More work will be needed to compare intervention types, doses and delivery systems across disease areas. - Researchers will also need to test whether the reported synergies translate into consistent benefits in larger human studies.

The bottom line: - The new review consolidates a large and growing human evidence base for sulforaphane, while making a case that formulation quality and bioavailability may be as important as the bioactive itself. - Read the published paper